

Keep out of reach of children
FOR ANIMAL TREATMENT ONLY

DOLOREX™

BUTORPHANOL TARTRATE INJECTABLE ANALGESIC FOR HORSES.

ACTIVE CONSTITUENT: BUTORPHANOL BASE (as tartrate) 10mg/mL

10 mL

Read entire label before use.

HANDLING PRECAUTIONS Warning may cause organ damage from repeated/prolonged oral exposure at high doses. Avoid breathing vapours.

FIRST AID If inhaled: remove to fresh air. For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.

ACCIDENTAL SELF-INJECTION Seek immediate medical attention - show this leaflet and/or SDS. Do not drive, as the effects of butorphanol includes sedation, dizziness and confusion. Effects may be reversed with an opioid antagonist.

DISPOSAL Dispose of any unused contents and container in an approved landfill.

See Safety Data Sheet for further information: www.intervet.co.nz

DESCRIPTION

Clear, colourless solution containing butorphanol tartrate 10mg/mL.

MODE OF ACTION

Centrally acting analgesic.

INDICATIONS

For the relief of moderate to severe pain in the horse, especially abdominal pain associated with colic and post-partum pain. Dolorex results in a prompt relief of pain, thus preventing possible visceral displacement and self-inflicted injury, and permitting a more thorough examination and appropriate therapeutic measures. Pain relief, however, is not so thorough or long-lasting that it masks the need of surgery.

CONTRAINDICATIONS

Should not be administered to horses with a history of liver or kidney disease.

If used in combination with detomidine – do NOT use in horses with pre-existing cardiac dysrhythmia or bradycardia. Do not use in impaction colic.

DOSAGE AND ADMINISTRATION

The recommended dosage in the horse is 0.1mg of butorphanol per kilogram of body weight by intravenous injection. This is equivalent to 5mL of Dolorex for each 500kg body weight.

Analgesic effects are seen within 15 minutes of injection and may last up to 60 minutes. Repeat treatments may be administered based on clinical response. For cases where longer duration of analgesia is required, an alternative therapeutic agent should be considered.

ADVERSE EFFECTS

The most commonly observed side effect is slight ataxia which may persist for 3-10 minutes. Mild sedation may occur in approximately 10% of horses. Pacing, reduction in gastrointestinal motility and depression of the cardiovascular system may also occur.

INCOMPATIBILITIES

Do not mix with other veterinary medicinal products.

WITHHOLDING PERIOD

Horses producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 63 days of the last treatment.

STORAGE

Store below 25°C. Protect from light. Do not refrigerate or freeze. Use within 28 days of opening.

Prescription Animal Remedy (**P.A.R**) Class II. For use only by, in the presence of, or under the control of a veterinarian.

Registered pursuant to the ACVM Act 1997, No. A6877. See www.nzfsa.govt.nz/acvm/ for registration conditions.

Approved pursuant to the HSNO Act 1996, HSR001963. See www.ermanz.govt.nz for controls.

Registered to:

Schering-Plough Animal Health Ltd
33 Whatakiti Street, Upper Hutt, NZ.
Phone 0800 800 543